Investing.com -- Eli Lilly shares were upgraded to Outperform at Leerink Partners, which cited “multiple waves of obesity treatment adoption drivers” and raised its price target to $1,104 from $886.
Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next ...
Fintel reports that on November 10, 2025, Leerink Partners maintained coverage of uniQure N.V. (NasdaqGS:QURE) with a ...
Eli Lilly and Company is positioned for substantial growth following significant regulatory and strategic developments.
Fintel reports that on November 10, 2025, Leerink Partners maintained coverage of Cogent Biosciences (NasdaqGS:COGT) with a ...
J.P. Morgan, Jefferies, Leerink Partners and Guggenheim Securities are acting as joint-book running managers for the proposed Equity Offering. LifeSci Capital is acting as lead manager and Raymond ...
WALTHAM, Mass. and BOULDER, Colo., Nov. 10, 2025 (GLOBE NEWSWIRE) -- (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, tod ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback